Energizer Holdings, Inc. (ENR) Gets in Touch With Its Feminine Side

Maybe we should have guessed it from the Energizer Bunny’s pink fur, but battery maker Energizer Holdings, Inc. (NYSE:ENR) is about to get more in touch with its feminine side.

Although it’s probably best known for its Energizer Holdings, Inc. (NYSE:ENR) and Eveready brands of consumer batteries, personal care products actually comprise the biggest source of the company’s revenues, some 58% of total net sales and 53% of operating profits last quarter. Feminine care products, however, have comprised just a small component of those revenues (4%), until now.

Energizer Holdings, Inc. (NYSE:ENR) has announced it will be buying Johnson & Johnson (NYSE:JNJ)‘s feminine hygiene products business for $185 million cash that it will roll into its existing Playtex division, which it acquired in 2008. Included will be Stayfree pads, Carefree liners, and the o.b. tampon brands in the U.S., Canada, and Caribbean, which currently enjoy some $250 million in annual sales. J&J will also throw in its Canadian manufacturing facility with it.

Energizer Holdings, Inc. (NYSE:ENR)’s feminine care business, like several of its other divisions, could stand a visit from the pink bunny. Revenues fell 8% last quarter to $46 million as promotional activity like couponing sapped strength, but overall it also blamed wetter weather on falling sales in products like sun care. With a broader product portfolio, however, Energizer is looking to capitalize on the greater sales opportunities it will develop. It notes having the ability to stock a whole endcap in a retail store with your products rather than just a shelf has a better chance of enhancing operating performance.

The feminine hygiene market has been shrinking despite a bewildering array of products on the store shelves (OK, bewildering to me), with sales falling 2% last year in the sanitary protection segment. Energizer Holdings, Inc. (NYSE:ENR)’s results have been indicative of that decline and though Johnson & Johnson (NYSE:JNJ)’s women’s health segment also saw revenues decline 2% in its March quarter, much of that was due to currency fluctuations. Operationally, sales inched up just under 1%.